Tuberc Respir Dis.  1984 Mar;31(1):17-24. 10.4046/trd.1984.31.1.17.

Multicentric-Multispeciality Clinical Trial on Ambroxol in Korea

• KMID: 2528785
• DOI: http://doi.org/10.4046/trd.1984.31.1.17

Abstract

The clinical effect of trans-4 〔(2-amino-3,5, -dibromobenzyl)-amino〕-cyclohexanol hydrochloride(ambroxol) and its effect on lung function were tested in 80 patients(20 patients with acute bronchitis, 20 patients with chronic bronchitis, 20 patients with acute rhinitis and 20 patients with maxillary sinusitis) Among expectorants, there are a considerable number of drugs which have been used without clarification of their pharmacological effects. Ambroxol, which is a newly developed expectorant, facilitates expectoration by lubricating the expectoration route of sputum, by decreasing the viscosity of sputum through dilution, by increasing mucociliary action, and by secretion of surfactant substances in the lung. We have studied the expectorant activity of ambroxol and observed the following clinical results. 1) Clinical improvement after treatment with ambroxol was as follows; cough( 81 %), frequency of sputum( 60%) , volume of sputum(56%). color of sputum(71%) , ease of expectoration(88%) , dyspnea(58%) , severity of rhinorrhea(73%), quality of rhinorrhea (72%), foul odor of rhinorrhea(52%) , nasal stuffiness(77%) , postnasal driP(73%) , and hyposmia (50%). 2) Clinical improvement of pulmonary function test appeared to be somewhat better in acute bronchitis than in chronic brochitis. 3) No remarkable side effect was observed except mild gastrointestinal symptoms, such as indigestion, nausea, vomiting and abdominal pain. 4) Ambroxol was also effective in the treatment of E.N.T. diseases because it stimulates surfactant-like substance production.